Articles On Race Oncology (ASX:RAC)

Race Oncology completed dosing stage of Phase, eyes Phase 2 trial Immutep presents trials data at ASCO 2022 meeting Clarity Pharma presents at the Jefferies Biotech Summit Race Oncology (ASX:RAC) has completed the dose escalation stage of...

Both ASX Small Cap and benchmark index are down about 0.5% A bleak forecast from Covid-stricken China hits resources stocks Appen in trading halt after jumping 30%     Local markets took a turn for the worse on Thursday after Chinese Prem...

The Race Oncology Ltd (ASX: RAC) share price edged higher before being frozen today. This comes after the pharmaceutical company requested its shares be placed in a trading halt. At the time of writing, Race Oncology shares are on ice at $...

Highlights: Race Oncology is riding high with governance approval for human trial of its new therapy Zantrene®. The cancer drug will be studied in patients with extramedullary Acute Myeloid Leukaemia (AML) or high-risk Myelodysplastic...

Race Oncology (RAC) receives governance approval for a clinical trial of Zantrene in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) Together with ethics approval and completion of site training due to start...

Race Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rhythm Biosciences has filed blood test ColoSTAT with the TGA Proteomics gets $400k government funding Race Oncology (ASX:RAC) has just recei...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Race Oncology (ASX:RAC) has received human ethics approval for its open-label clinical trial of Zantrene in patients with extramedullary Acute Myeloid Leukaemia or high-risk Myelodysplastic Syndrome.

The ASX200 has taken a 0.5% hit on Wednesday, with the tech sector giving back all the previous session’s gains after Wall Street fell and the tech-laden Nasdaq Composite lost 2.3% overnight. The overnight session was dominated by comments...

Race Oncology (RAC) receives human ethics approval for its clinical trial of Zantrene in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) Before patients can be enrolled and treated at the lead site, Race must...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Race Oncology (ASX:RAC) has shared the interim results from the extramedullary acute myeloid leukaemia preclinical program led by cancer researcher, Associate Professor Nikki Verrills.

Race Oncology (RAC) is rapidly advancing its cancer drug as a possible new treatment option for patients with extramedullary acute myeloid leukaemia The news comes after a preclinical program, which found low doses of Zantrene, in combinat...

Race Oncology (ASX:RAC) has shared the final results from the clear cell renal cell carcinoma preclinical program led by eminent cancer researcher, Associate Professor Nikki Verrills of The University of Newcastle and Hunter Medical...

Shares in Race Oncology Ltd (ASX: RAC) are soaring and trading 5% in the green at $2.77 apiece. At one point investors had bid up the share price to $2.99 before it levelled off. The company’s lead drug compound, Zantrene, is back in the...

Race Oncology (RAC) has revealed its Zantrene product can kill a range of kidney cancer cells both on its own and in combination with existing cancer treatments The company recently completed a preclinical program testing the drug on the m...

“Advanced kidney cancer has a large unmet need for improved treatment options and Zantrene in combination with existing treatments may offer new hope for patients with this devastating disease," says chief scientific officer Dr Daniel Tille...

Shares in Race Oncology Ltd (ASX: RAC) soaring today to finish trading 14% higher in the green. The Race Oncology share price flamed higher despite no market-sensitive information from the company’s camp, nor was there any major upsets in...

Today wasn’t a great day for most ASX shares. The All Ordinaries Index (ASX: XAO) ended up losing 0.93% over this Tuesday’s trading session. But that loss was eclipsed by the Race Oncology Ltd (ASX: RAC) share price. Race shares ended up f...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Race Oncology (ASX: RAC) has announced the publication of a peer-reviewed preclinical study that has identified additional drug combinations showing synergy with its cancer-fighting drug Zantrene when tested in acute myeloid leukaemia (AML)...

Race Oncology (RAC) announces its lead Zantrene drug has been found to show synergy with several other drug combinations when tested in Acute Myeloid Leukaemia cells Researchers from the MD Anderson Cancer Center in Texas found a number of...

Inoviq (ASX:IIQ) has been granted a Brazilian patent covering the use of BARD1 isoforms in lung and colorectal cancer. Specifically, the patent covers a method for detecting the presence of the specific BARD1 isoforms, and a method for disc...

“This work provides further preclinical data to support our upcoming Phase 1b/2 extramedullary AML trial in Australian and Europe, where patients will be treated with Zantrene in combination with decitabine or cytarabine,” CHM chief scienti...

They say if you can’t measure it, you can’t manage it – and that holds particularly true when it comes to sustainability. While all the talk has been on achieving net zero by 2050, little has been done to address the lack of mandatory repor...

Disclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and associated entities, own 13,631,579 ALA shares. S3 Consortium Pty Ltd has been engaged by ALA to share our commentary on the progress of our in...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Race Oncology (ASX: RAC) executive director and entrepreneur Dr Daniel Tillett has joined smart energy software as a service company Simble Solutions (ASX: SIS) to help drive commercialisation of its CarbonView and SimbleSense ESG (environm...

The ASX200 has vacillated all of Monday in a whiny, unattractive way for a major global index. Like a Kardashian (name one) unable to get out of bed, the heavyweight financial names and the major miners are just dragging everyone lower, dow...

Christina Manfre, a partner at PKF Sydney, will provide leadership to Race Oncology’s financial analysis, reporting and strategic financial needs.

Race Oncology (RAC) reports $1.8 million in cash outflows for the quarter, an increase from the $931,000 in outflows recorded in the previous quarter The company spent $890,000 during the period for research and development RAC’s focus is...

Key points The Race Oncology share price is up as high as 2.8% today A new discovery relating to heart protection has been made Oversubscribed share purchase plan has raised $29.7 million The Race Oncology Ltd (ASX: RAC) share price is...

Key points Firebrick Pharma will debut on the ASX at 12:30pm AEDT today The company is developing a nasal spray to help treat the common cold. It’s product will also undergo a COVID-19 trial Shares in the company were offered for 20 cents...

“The increased refund for FY21 is representative of the enhanced investment we made into R&D as we expanded our Zantrene clinical and supporting programs," says MD.

Returns in the ASX healthcare basket were fairly robust throughout 2021. Sector earnings saw a return to pre-COVID levels as patient and service volumes began to normalise as well. The S&P/ASX 200 Health Care Index (ASX: XHJ) has clim...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

“The number of applications reflects enthusiasm for the significant potential of our lead drug Zantrene and this enables us to implement our planned clinical and drug development plans across the three-pillar program,” managing director and...

Race Oncology (ASX: RAC) is closing out 2021 with an extra $29.7 million in the bank after completing a heavily oversubscribed share purchase plan that saw almost $44 million in applications. Under the share purchase plan, eligible existing...

Race Oncology (RAC) raises $29.7 million in an oversubscribed share purchase plan The company received applications totalling almost $44 million from 2340 shareholders, with the funds to be used to accelerate the company’s clinical and dev...

The Race Oncology Ltd (ASX: RAC) share price is climbing today on the back of the company’s latest capital raise. During morning trade, the pharmaceutical company’s shares are up 3.64% to $3.42 apiece. What did the company announce? Invest...

After identifying its heart protective effects, Race Oncology (ASX: RAC) has extended the collaboration with the University of Newcastle for its Zantrene (bisantrene dihydrochloride) anti-cancer drug. Earlier this week, Race revealed precli...

This strategically important collaboration will underpin a cardio-protective Phase 2b clinical trial in cancer patients at high risk of anthracycline-induced heart damage, which is expected to begin treating patients in late 2022.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Clinical stage RNA focused company targeting multiple cancer indications with estimated annual oncology revenues of >US$2.6 billion

“Zantrene is the first anti-cancer agent that we have found to exhibit a cardioprotective profile while being synergistically effective as an anti-cancer treatment," says University of Newcastle associate professor Doan Ngo.